8-K: AnaptysBio Sues Tesaro & GSK Over Collaboration Breach

AnaptysBio initiates legal action against Tesaro and GSK, alleging material breaches of their Collaboration and Exclusive License Agreement and tortious interference.

Summary

• AnaptysBio, Inc. filed a Verified Complaint in Delaware Chancery Court on November 20, 2025, against TESARO, Inc. and its corporate parent, GlaxoSmithKline (GSK).
• The complaint alleges TESARO materially breached the Collaboration and Exclusive License Agreement and GSK tortiously interfered with the agreement.
• AnaptysBio claims TESARO violated exclusivity obligations by participating in clinical trials with competing PD-1 antagonists, such as Keytruda, against Jemperli.
• AnaptysBio also alleges TESARO failed to use 'Commercially Reasonable Efforts' to obtain optimum commercial return for Jemperli, instead favoring GSK's antibody-drug conjugate (ADC) product candidates.
• TESARO, without prior notice, filed a counter-lawsuit against AnaptysBio on the same day, claiming AnaptysBio breached the Collaboration Agreement by improperly alleging TESARO's breach and seeking injunctive relief.
• AnaptysBio considers TESARO's claims entirely without merit and plans to pursue all legal remedies, including dismissal and potential further litigation.
• A similar dispute in 2020 with GSK regarding Zejula and Keytruda resulted in a settlement that included a cash payment, a royalty on Zejula, and a substantial increase in royalties on Jemperli sales for AnaptysBio.
• Milestone and royalty payments to AnaptysBio under the Collaboration Agreement are expected to continue during the legal proceedings.
• An expedited trial schedule has been requested, with the trial anticipated in July 2026.

Sentiment

Score: 3

Explanation: The filing details a significant legal dispute with a key partner and its parent company, including a counter-suit. While AnaptysBio is defending its rights, the litigation introduces substantial uncertainty, potential costs, and risks to a core collaboration agreement. The previous successful settlement offers some positive context, but the current situation is inherently negative due to the ongoing conflict and potential for agreement termination.

Positives

• AnaptysBio is actively defending its contractual rights and intellectual property related to the Collaboration Agreement.
• A previous legal dispute with GSK in 2020 resulted in a favorable settlement for AnaptysBio, including increased royalties on Jemperli and a cash payment, indicating a history of successful dispute resolution.
• Milestone and royalty payment obligations to AnaptysBio pursuant to the Collaboration Agreement are expected to continue during the legal proceedings.

Negatives

• The initiation of new, complex litigation against a major partner (TESARO) and its parent (GSK) introduces significant legal costs and resource drain.
• TESARO has filed a counter-lawsuit against AnaptysBio, adding complexity and further legal uncertainty to the situation.
• The dispute could lead to the potential termination of the Collaboration Agreement, which would impact future revenue streams from Jemperli.
• Significant management time and company resources will be diverted to managing the legal proceedings.
• Uncertainty surrounds the outcome of the court proceedings and the nature of any remedies AnaptysBio may obtain.

Risks

• The potential termination of the Collaboration Agreement.
• Uncertainty regarding the timing and potential outcome of proceedings in Delaware Chancery Court.
• The possibility that Jemperli may not be returned to AnaptysBio.
• Uncertainty regarding the nature of remedies AnaptysBio may obtain in such proceedings.
• General risks and uncertainties described under the heading 'Risk Factors' in documents the company files from time to time with the Securities and Exchange Commission.

Future Outlook

The company anticipates ongoing legal proceedings with TESARO and GSK, with a trial expected in July 2026. The outcome could include the potential termination of the Collaboration Agreement, the return of Jemperli to AnaptysBio, or other remedies. Milestone and royalty payments are expected to continue during the proceedings.

Management Comments

• AnaptysBio contends that Tesaro's claims are entirely without merit and intends to pursue all appropriate legal remedies against Tesaro, including dismissal of such claims at the earliest opportunity and the potential for additional litigation.

Industry Context

This legal dispute highlights the inherent complexities and risks associated with collaboration and licensing agreements in the pharmaceutical and biotechnology sectors. Such agreements are crucial for drug development and commercialization but often involve intricate terms regarding exclusivity, commercialization efforts, and intellectual property. Disputes like this can arise when partners' strategic priorities diverge, especially when one partner (GSK/TESARO) has competing products (Keytruda, ADCs) that could potentially cannibalize the market for the licensed product (Jemperli). The previous settlement in 2020 indicates a pattern of disputes over these collaboration terms, underscoring the high stakes involved in oncology drug markets.

Comparison to Industry Standards

• Collaboration disputes are not uncommon in the biopharmaceutical industry, particularly concerning exclusivity clauses and 'commercially reasonable efforts' obligations. Similar disputes have arisen between companies like Amgen and Takeda over oncology drug rights, or between smaller biotechs and larger pharma partners regarding development milestones and market prioritization.
• The previous settlement in 2020, which resulted in increased royalties and a cash payment for AnaptysBio, suggests that AnaptysBio has a history of successfully asserting its rights in such disputes. This could be compared to cases where smaller biotechs have successfully renegotiated terms or received significant compensation from larger partners for alleged breaches.
• The involvement of a major pharmaceutical company like GSK, with its broad portfolio including competing assets like Keytruda and various ADCs, exemplifies the challenges smaller partners face in ensuring their licensed products receive adequate focus and resources.

Legal Proceedings

• AnaptysBio, Inc. filed a Verified Complaint in Delaware Chancery Court on November 20, 2025, against TESARO, Inc. and GlaxoSmithKline (GSK).
• The complaint alleges TESARO materially breached the Collaboration and Exclusive License Agreement by violating exclusivity obligations (participating in trials with competing PD-1 antagonists like Keytruda) and failing to use 'Commercially Reasonable Efforts' for Jemperli.
• The complaint also alleges GSK tortiously interfered with the Collaboration Agreement.
• TESARO, Inc. initiated a lawsuit against AnaptysBio on November 20, 2025, claiming AnaptysBio breached the Collaboration Agreement by improperly alleging TESARO's breach, and seeks injunctive relief.
• AnaptysBio intends to pursue dismissal of TESARO's claims and potentially additional litigation.
• An expedited trial schedule is requested, with trial anticipated in July 2026.
• Milestone and royalty payment obligations to AnaptysBio continue to be due during the proceedings.

Stakeholder Impact

• Shareholders face increased uncertainty due to ongoing litigation, potential legal costs, and risks to future revenue streams from Jemperli. The outcome could significantly impact the company's valuation.
• Employees may experience increased pressure or distraction due to the legal dispute, particularly those involved in the Jemperli program or legal department.
• Customers/Patients may see potential impacts on the availability or development trajectory of Jemperli or competing PD-1 antagonists, depending on the legal outcome.
• Partners (TESARO/GSK) also face legal costs, reputational risk, and potential disruption to their oncology programs.

Next Steps

• AnaptysBio intends to pursue all appropriate legal remedies against TESARO, including dismissal of TESARO's claims at the earliest opportunity and potential additional litigation.
• The parties have agreed to request an expedited schedule with the Delaware Chancery Court.
• Trial is anticipated in July 2026.

Key Dates

Recommendation

The filing details significant ongoing litigation with a key partner and its parent company, including a counter-suit. While AnaptysBio has a history of successfully resolving similar disputes, the current situation introduces substantial uncertainty, potential legal costs, and risks to a core collaboration agreement for Jemperli. The outcome of the trial in July 2026 is unknown, and the potential termination of the agreement could significantly impact future revenue. Given the high stakes and the current legal entanglement, a 'hold' recommendation is appropriate until there is more clarity on the legal proceedings and their potential financial implications. Investors should monitor developments closely.

Keywords

AnaptysBio, TESARO, GSK, Collaboration Agreement, Exclusive License, Jemperli, PD-1 antagonist, Keytruda, Zejula, Delaware Chancery Court, litigation, breach of contract, tortious interference, biotechnology, pharmaceuticals, oncology, antibody-drug conjugate, ADC, royalties, intellectual property